Kowa Company, Ltd.
Across our entire group, we have more than 120 years of experience in business and we are proud of our Japanese influence and heritage. Since we were founded in 1894 as Hattori Kanesaburo Wholesale Store (a cotton cloth wholesaler) we have nurtured aspirations to be a global, modern and cutting-edge company.
Kowa Pharmaceutical Europe Co. Ltd.
By the middle of the last century, we recognised that the pharmaceutical industry presented significant challenges and offered multiple opportunities to help us shape an innovative, forward-looking and global network that could bring many health care benefits to society. So in 1947, the Kowa Pharmaceutical division was born.
Click the years on the timeline above to discover more about Kowa through the years.
If you would prefer to watch the story of Kowa in full then click here
Electronics and optics division is established
Pharmaceutical division is established
Kowa Shinyaku Co., Ltd. is established
Tokyo Research Laboratory opens and Fuji Factory is constructed for drug production
Kowa spotting scopes are the official scopes for sports shooting at the Tokyo Olympic Games
Hamamatsu Factory is constructed for manufacture of the medical equipment
Kowa Research Institute Inc. is established in California, USA
Kowa Pharmaceutical Europe Co. Ltd. is established
Pitavastatin (Livalo®), for the treatment of dyslipidemia, is launched in Japan
Nikken Chemicals Co., Ltd. becomes a subsidiary of Kowa
Kowa fully acquire Nikken Chemicals Co., Ltd. and changes its name to Kowa Pharmaceutical Co. Ltd.
Eyecon Co, Ltd. (current Kowa Eyecon Co., Ltd.), manufacturer of intraocular lenses, is established
Kowa launch their first intraocular lens (IOL) for cataract patients in Japan ─ AvanseeTM
Livalo® is launched in China
Kowa and Brigham and Women’s Hospital (BWH) open The Center for Interdisciplinary Cardiovascular Sciences (CICS) in Boston
Avansee™ Preset, the first preloaded IOL system in Kowa’s IOL portfolio, is launched in Japan
Kowa launch the world’s first 2D and 3D digital retinal camera
Livalo® is launched in the USA
Livalo® Marketing Authorization is obtained in the EU
Livalo® is launched in Europe
K-877 key data (PPAR-α agonist), for the treatment of dyslipidemia, is presented at EAS
Anagliptin (DPP-4 inhibitor SUINY®), for the treatment of type 2 diabetes mellitus, is launched in Japan
Tofogliflozin hydrate (SGLT2 inhibitor DEBERZA®), for the treatment of type 2 diabetes mellitus, is launched in Japan
Kowa expand their IOL portfolio with the launch of Avansee™Preset small incision in Japan
Avansee™Preset launched in Europe
Ripasudil Hydrochloride Hydrate (Rho kinase inhibitor GLANATEC®) launched in Japan for the treatment of glaucoma and ocular hypertension
Livalo® approved for a new indication in Japan – the treatment of paediatric familial hypercholesterolemia
Avansee™Preload1P launched in Japan – Kowa’s first 1-piece intraocular lens
Avansee™Preload1P launched in Europe
Livalo® approved for a new indication in EU - the treatment of pediatric hypercholesterolemia and mixed dyslipidemia
PARMODIA® for the treatment of dyslipidemia (including familial type) is launched in Japan
“what will the future bring?”